Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
Depending on the age and needs of the individual, family-based treatment may also be integrated
10.1172/jci.insight.90777 JCI Insight 101 LiQ
Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A
Ingredients: Water, Centella Asiatica Extract (20.5%), Butylene Glycol, Glycerin, Dipropylene Glycol, Niacinamide (20,000ppm), Hydroxyethyl Urea, Sodium Hyaluronate, Allantoin, Panthenol, Glutathione (1,000ppm), Nelumbo Nucifera Extract, Artemisia Annua Extract, Oryza Sativa (Rice) Extract, Saccharomyces Ferment, Solanum Melongena (Eggplant) Fruit Extract, Melaleuca Alternifolia (Tea Tree) Leaf Extract, Hydrolyzed Collagen, Beta-Glucan, Hippophae Rhamnoides Fruit Extract, Adenosine, Madecassic Acid, Asiaticoside, Asiatic Acid, Squalane, Caprylic/Capric Triglyceride, Hydrogenated Lecithin, Glyceryl Stearate, Cholesterol, Xanthan Gum, Propanediol, Hydroxyacetophenone, 1,2-Hexanediol, Ethylhexylglycerin, Dipotassium Glycyrrhizate, Styrene/Acrylates Copolymer, Citric Acid, Sodium Citrate
Regarding efficacy, in the 137 analyzed patients, the change from baseline to the end of observation in Visual Analogue Scale score (VAS) was statistically significant, ranging from 75.9 1.56 to 51.9 1.99 ( p 40 according to the VAS score (Visual Analogue Scale 0100), who, between 2017 and 2022, were prescribed ALC, regardless of the concomitant pharmacological FMS therapy (add-on treatment)
Many patients who do not meet hypermobile EDS criteria and do not have clear evidence for another specific syndrome will meet criteria for hypermobility spectrum disorders
US$ 24.66
US$ 23.02
US$ 21.28
US$ 23.03
US$ 28.39
US$ 21.04
US$ 25.45